Bone microstructure in proton pump inhibitor users.

Abstract

We assessed skeletal microstructure and stiffness in proton pump inhibitor (PPI) users compared to non-users with high resolution peripheral quantitative computed tomography (HRpQCT) and microfinite element analysis (μFEA) and other modalities. Relationships between PPI dose/frequency and bone parameters were evaluated. We cross-sectionally assessed skeletal health in 601 older (≥age 65years) adults (130 PPI users and 471 non-users) participating in a multi-ethnic population-based study of aging. PPI users tended to have more comorbidities and take more medications than non-users. Female PPI users (n=100) were more likely to be non-Caucasian, shorter with higher BMI, and more likely to have diabetes, lower physical activity and be using anti-depressants and thiazide diuretics compared to non-users (n=302). Male PPI users (n=30) were more likely to have liver disease than non-users (n=169). In women, historical fractures (53.0% vs. 43.4%, p=0.05) and falls (38% vs. 26.8%, p=0.04) tended to be more frequent in PPI users compared to non-users. Number of falls was higher in women reporting daily rather than intermittent PPI use (1.8/year vs. 1.0/year, p<0.001). In women, there were no differences in any HRpQCT or μFEA parameter. By HRpQCT, covariate-adjusted cortical volumetric bone density (Ct.vBMD) was 4.2% lower in male PPI users vs. non-users at the tibia (p=0.04), but this did not result in reduced stiffness. There were no other differences by HRpQCT at the tibia or radius. PPI use was not associated with altered skeletal microstructure or stiffness in elderly men and women. The results do not support a relationship between PPI use and microstructure.